CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors.
To determine the possible functional significance of CD40 expression on human non-small cell lung carcinomas and to assess the potential of CD40 as a therapeutic target, 18 lung tumor cell lines were established from biopsy tissues and were monitored for phenotypic changes on the cell surface and alterations in tumor cell proliferation after the ligation of CD40 with a trimeric fusion protein complex of CD40 ligand (CD40Lt). CD40 cross-linking resulted in up to a 6-fold increase in the surface expression of major histocompatibility complex (MHC) class I, Fas and intracellular adhesion molecule (ICAM)-1 in a subset of tumors expressing the highest levels of CD40. Suppression of tumor proliferation was seen after the ligation of CD40 on CD40Lt-responsive cell lines. The suppression was dose dependent, reversible and resulted from a delay of the tumor cells entering S-phase. No change in the cell phenotype or in proliferation were observed in CD40-negative tumors or in tumors expressing moderate-to-low levels of CD40 after incubation with CD40Lt. CD40-negative tumors transfected with the CD40 gene expressed high levels of CD40 on their surface, but were also unresponsive to CD40Lt cross-linking of CD40. Our data establish that CD40 is required (but not sufficient) for transducing a signal that results in phenotypic changes in human lung tumors and suppression in their proliferation. We conclude that CD40 on non-small cell lung tumors may represent a potential therapeutic target, but only on a subset of the CD40+ tumors.
Yamada
M
M
Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Shiroko
T
T
Kawaguchi
Y
Y
Sugiyama
Y
Y
Egilmez
N K
NK
Chen
F A
FA
Bankert
R B
RB
D017209:Apoptosis; D019013:CD40 Antigens / Q000096:biosynthesis* / Q000378:metabolism; D023201:CD40 Ligand / Q000096:biosynthesis* / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism*; D002453:Cell Cycle; D002455:Cell Division; D004396:Coloring Agents / Q000494:pharmacology; D003432:Cross-Linking Reagents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis*; D008175:Lung Neoplasms / Q000378:metabolism*; D008285:Major Histocompatibility Complex; D010641:Phenotype; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D016196:S Phase; D015398:Signal Transduction; D013778:Tetrazolium Salts / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D013997:Time Factors; D014162:Transfection; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000096:biosynthesis*
D019013:CD40 Antigens; D004396:Coloring Agents; D003432:Cross-Linking Reagents; D011993:Recombinant Fusion Proteins; D013778:Tetrazolium Salts; D013844:Thiazoles; D019014:fas Receptor; D018799:Intercellular Adhesion Molecule-1; D023201:CD40 Ligand; C022616:thiazolyl blue